Good Products announced the availability of its new validation project management tool, ValMan. The software helps life sciences organizations store and manage validation protocols and test plans, enabling compliance with the regulations. It allows documents and activities for specific projects to be stored in separate secure areas, while a set of predetermined workflow templates facilitates effective project management. ValMan customers can choose from a database of over 5,000 validation template documents covering facilities, cleaning, manufacturing equipment, laboratory equipment and computerized systems for biopharma, laboratory and clinical research organizations to pre-populate their validation document libraries. Here’s the release.

Encorium Group announced that it received a letter from Nasdaq Listing Qualifications on August 6, 2008, stating that solely as a result of the resignation of Paul J. Schmidt from Encorium’s board of directors, effective as of June 16, 2008, Encorium was not then in compliance with Nasdaq’s independent director requirements as set forth in marketplace rule 4350. The company expects its board of directors to change following the completion of its previously announced non-binding letter of intent to combine with Fine Success Investments. In the interim, effective August 11, 2008, Kenneth Borow, Encorium Group’s president and chief medical and strategic development officer, stepped down from the board of directors in order for Encorium to remain compliant with Nasdaq’s independent director requirement. On August 11, 2008, the company received a letter from Nasdaq indicating that it recognized the change described above and that the company is now in compliance with marketplace rule 4350. Here’s the release.

Biovail announced financial results for the three-month and six-month periods ended June 30, 2008. Total revenues for the three months ended June 30, 2008, were $186.1 million. Second-quarter 2008 net income was a loss of $25.3 million, compared with net income of $67.8 million for the corresponding 2007 period. “We have made progress in the implementation of our new strategic focus and the transformation of Biovail,” said Biovail’s CEO Bill Wells. “Our cost-efficiency initiatives are beginning to produce results, our business development efforts are extremely active, and Biovail’s balance sheet and cash balances are robust.”

PRA International appointed Tami Klerr-Naivar as senior VP of business development. Klerr-Naivar brings a strong portfolio of broad sales expertise and specific therapeutic experience. “PRA is excited to have Tami join our team,” commented Terry Bieker, CEO of PRA. “Her strategic focus and well rounded therapeutic, operational and sales experience align perfectly with our business development strategy.” Here’s the release.

i3 Drug Safety epidemiologists will present the results of 17 key studies at the 24th annual International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) next week in Copenhagen, Denmark. Most of these studies draw on information from the large, integrated health care claims database of i3’s parent company Ingenix, an industry leader in health information, technology and consulting.

Parexel has concluded its $192 million acquisition of ClinPhone. The British clinical technology suite will be combined with Parexel’s technology unit, Perceptive Informatics. Because a company acquired by ClinPhone had already settled with Datasci, a patent troll, the acquisition allows Parexel to avoid ongoing uncertainty over litigation now bedeviling several of Parexel’s largest competitors. Josef von Rickenbach, Parexel chairman and CEO, said: “We believe this acquisition further solidifies Parexel’s leadership in providing integrated clinical and technology expertise. Combining the sophisticated, in-depth capabilities of Perceptive and ClinPhone represents a major step forward for Parexel in meeting increased industry demand for a truly comprehensive eclinical platform.”

Have a news release? Send it to .